|
Pregnancy associated with hepatotoxicity regardless of
nevirapine exposure, USA.
|
|
|
|
|
| Article Type: | Brief article |
| Subject: |
Nevirapine
(Complications and side effects) Highly active antiretroviral therapy (Complications and side effects) Highly active antiretroviral therapy (Demographic aspects) Pregnant women (Physiological aspects) Liver diseases (Risk factors) |
| Pub Date: | 05/01/2010 |
| Publication: | Name: Reproductive Health Matters Publisher: Reproductive Health Matters Audience: General Format: Magazine/Journal Subject: Family and marriage; Health; Women's issues/gender studies Copyright: COPYRIGHT 2010 Reproductive Health Matters ISSN: 0968-8080 |
| Issue: | Date: May, 2010 Source Volume: 18 Source Issue: 35 |
| Geographic: | Geographic Scope: United States Geographic Code: 1USA United States |
|
|
|
| Accession Number: | 236247768 |
| Full Text: |
This article challenges the notion that nevirapine (a commonly used
antiretroviral) is uniquely associated with hepatotoxicity during
pregnancy. Data flora 2,050 HIV-positive pregnant and 1,229 HIV-positive
non-pregnant women all on HAART from three large prospective cohort
studies in the US showed that pregnancy itself was significantly
associated with increased hepatotoxicity in HIV-positive women. The
association was seen regardless of prior HAART and nevirapine exposure
history. Contrary to previous reports, the investigators did not find an
increase in hepatotoxicity among pregnant women exposed to nevirapine,
including nevirapine-naive women with high CD4 cell counts. Pregnancy
may provide a unique physiology that predisposes women to drug-induced
hepatotoxicity. Consequently, whenever feasible, liver enzymes should be
monitored among pregnant HIV-positive women on HAART. The findings are
highly relevant for developing countries where nevirapine is a common
component of first-line HAART, including during pregnancy. It is
important to emphasise that the hepatotoxicity previously noted in
patients taking continuous nevirapine has not been seen when nevirapine
is used as a single, intrapartum dose. (1) (1.) Ouyang DW, Shapiro DE, Lu M, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 2009; 23(18):2425-30. |
| Gale Copyright: | Copyright 2010 Gale, Cengage Learning. All rights reserved. |
Previous Article: HAART during pregnancy and breastfeeding in the
developing world.
Next Article: New WHO guidelines on PMTCT and infant feeding.
Next Article: New WHO guidelines on PMTCT and infant feeding.